期刊文献+

抗凝血药物临床应用的现状及研究进展 被引量:17

Clinical practice of anticoagulants:status guo and research progress
下载PDF
导出
摘要 国内外对抗凝血药物研究进展迅速,针对不同靶点、不同作用机制的新型药物正在进行临床实验或业已上市。新型抗凝血药物凭着它本身的优势将逐渐代替传统抗凝药物。 At present,the study on anticoagulants develops quickly in recent decades all over the world.The emerging oral anticoagulant agents have target selective and multiple mechanisms,which are undergoing clinical experiment or have gone on the market.The novel anticoagulants will replace gradually traditional anticoagulant agents depending on their inherent advantages.
作者 王秀 夏泉
出处 《安徽医药》 CAS 2011年第10期1189-1192,共4页 Anhui Medical and Pharmaceutical Journal
基金 安徽省高等学校自然科学研究项目(NoKJ2008B286)
关键词 抗凝血药物 Ⅹa因子 凝血酶 anticoagulants factor Xa thrombin
  • 相关文献

参考文献32

  • 1Huo MH,James M.Extended thromboprophylaxis with low-molecular-weight heparins after hospital discharge in high-risk surgical and medical patients:A review[J].Clin Ther,2009,31(6):1129-41.
  • 2Gilles M,Richard G,Harvey DW,et al.Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention:1-year results from the steeple(safety and efficacy of enoxaparin in percutaneous coronary intervention patients,an international randomized evaluation)trial[J].JACC,2009,11(2):1083-91.
  • 3Tetri S,Hakala J,Juvela S,et al.Safety of low-dose subcutaneous enoxaparin for the prevention of venous thromboembolism after primary intracerebral haemorrhage[J].Thromb Res,2008,123:206-12.
  • 4Gibson CM,Murphy SA,Montalescot G,et al.Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial[J].J Am Coll Cardiol,2007,49:2238-46.
  • 5马培奇.抗凝血药物现状及其研发动态[J].上海医药,2009,30(8):379-380. 被引量:6
  • 6Ansell J.Long-term anticoagulation:The prospects for alternatives to warfarin[J].Semin Vasc Surg,2005,18:134-8.
  • 7Rashid MA,Parker MJ.Anticoagulation management in hip fracture patients on warfarin[J].Int J Care Injured,2005,36:1311-5.
  • 8Haas S.Rivaroxaban-an oral,direct Factor Xa inhibitor-lessons from a broad clinical study programme[J].Eur J Haematol,2009,82:339-49.
  • 9Eriksson BI,Borris LC,Friedman RJ,et al.Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty[J].N Engl J Med,2008,358(26):2765-75.
  • 10Lassen MR,Ageno W,Borris LC,et al.Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty[J].N Engl J Med,2008,358(26):2776-86.

二级参考文献26

  • 1王琪琳,曲爱琴,王海仁.海带硫酸多糖的降解、分离纯化及理化性质分析[J].药物生物技术,2004,11(5):316-320. 被引量:19
  • 2马夏军,岑颖洲,邱玉明,许少玉.超声波辅助过氧化氢氧化降解制备相对低分子质量异枝麒麟菜硫酸多糖[J].中国海洋药物,2005,24(4):10-13. 被引量:20
  • 3芮雯,岑颖洲,李药兰,伍秋明,王一飞,张美英.带形蜈蚣藻硫酸多糖的提取、分析及其抗病毒活性[J].中国海洋药物,2006,25(2):12-16. 被引量:24
  • 4中华人民共和国药典编委会.中华人民共和国药典(2005·一部)[S].北京:化工出版社,2006.
  • 5李时珍.本草纲目(校点本)[M].北京:人民出版社,1982.2846-2853,2856.
  • 6药用动物编写组.中国药用动物志[M].天津:天津科技出版社,1979.8-10.
  • 7Mariana S P,Ana-Cristina E S,Ana-Paula V,et al.A 2-sulfated,3-linked-α-L-galactan is an anticoagulant polysaccharide[J].Carbohydr Res,2002,337(21-23):2231-2238.
  • 8Groth T,Wagenknecht W.Anticoagulant potential of regioseselective derivatized cellulose[J].Biomaterials,2001,22(8):2719-2729.
  • 9Mulloy B,Mourao P A S,Gray E.Structure/function studies of anticoagulant sulphated polysaccharides using NMR[J].J Biotechnol,2000,77(1):123-135.
  • 10Wang X,Yuan Y,Wang K,et al.Deproteinization of gellan gum produced by Sphingomonas paucimobilis ATCC 31461[J].J Biotechnol,2007,(128):403-407.

共引文献50

同被引文献177

引证文献17

二级引证文献136

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部